Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
Stopped early · Not applicable
Conditions studied: Breast Cancer
In brief
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well erlotinib works in treating women undergoing surgery for stage I, stage II, or stage III breast cancer.
Key facts
- Study ID
- NCT00503841
- Run by
- Barbara Ann Karmanos Cancer Institute
- People needed
- 44
- Starts
- 2007-12-01
- Expected to finish
- 2010-05-01
- Last updated by the study team
- 2019-04-30
Who can join
Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.